- Low testosterone is a diagnosis, not a single number. Guidelines want two early-morning tests below the normal range (the urologists' cut-off is 300 ng/dL) plus symptoms. By one strict definition, only 2.1% of men aged 40–79 in a large European study qualified
- The heart question has a better answer now. In TRAVERSE, 5,246 men aged 45–80 with low testosterone and high heart risk had major heart events at the same rate on testosterone gel as on placebo (7.0% vs 7.3%)
- It wasn't risk-free. Atrial fibrillation, acute kidney injury, lung clots and fractures were more common with testosterone. In 2025 the FDA dropped cardiovascular language from the boxed warning and added a blood pressure warning to products that lacked one
- Benefits are real but narrow: sex drive, bone density and anemia improve; mood and energy improve only slightly; it doesn't prevent diabetes or treat depression
- Testosterone can shut down sperm production. Men who may want children should say so before starting
Somewhere between 40 and 60, many men notice they're more tired, less interested in sex and softer around the middle, and an advert tells them the answer is "low T". Some of them are right. Many aren't. And until recently nobody could say with confidence whether testosterone therapy was safe for the heart.
A trial called TRAVERSE changed that. Here's who actually has low testosterone, what the biggest safety trial found (including the parts headlines skipped), what testosterone does and doesn't do, and what to ask before starting. It isn't medical advice: it's the evidence to take to your doctor.
Low T Is a Diagnosis, Not a Number
Evidence: Strong — consistent major guidelinesTestosterone is highest in the morning and falls during the day, and one low result often isn't low the next time. So both major US guidelines set a high bar. The American Urological Association (AUA) guideline, published in 2018 and reaffirmed in 2024, uses a total testosterone below 300 ng/dL as a reasonable cut-off, based on two early-morning measurements on separate occasions, and makes the diagnosis only when low levels come with symptoms or signs (AUA). The Endocrine Society's 2018 guideline agrees: diagnose only in men with symptoms and signs, confirm with a repeat morning fasting test, and don't screen the general population. Its reference point is a lower limit of 264 ng/dL in healthy non-obese young men (Bhasin, JCEM 2018).
A proper workup goes further than one blood test:
- LH and FSH, the pituitary signals to the testes, to tell a testicular problem from a pituitary one. The Endocrine Society notes that biotin supplements interfere with these tests and should be stopped at least 72 hours before.
- Prolactin when testosterone is low and LH is low or low-normal (AUA).
- Free testosterone when total testosterone is borderline, or with obesity or type 2 diabetes, which lower the binding protein SHBG (Endocrine Society).
- PSA and hematocrit before starting; the AUA says PSA in all men over 40.
How common is it really?
The European Male Ageing Study surveyed a random sample of 3,369 men aged 40 to 79. Only three symptoms, all sexual, showed a consistent link with low testosterone: poor morning erections, low sexual desire and erectile dysfunction. The researchers defined late-onset hypogonadism as all three plus a total testosterone below 11 nmol/L (320 ng/dL) and low free testosterone. By that strict definition, 2.1% qualified (Wu, NEJM 2010; ACP Internist).
Prescribing went the other way. In US insurance data, the share of men over 40 using testosterone rose from 0.81% in 2001 to 2.91% in 2011, and about a quarter of new users hadn't had their level tested in the year before starting (UTMB, on Baillargeon, JAMA Intern Med 2013).
TRAVERSE and the Heart Question
Evidence: Strong — large randomised placebo-controlled trialFor years, small studies pointed in opposite directions on testosterone and heart attacks. TRAVERSE, run at 316 US sites and published in the New England Journal of Medicine in June 2023, was designed to settle it (Lincoff, NEJM 2023). It enrolled 5,246 men aged 45 to 80 with symptoms, two fasting morning testosterone results below 300 ng/dL, and existing cardiovascular disease or high risk. They used a daily 1.62% testosterone gel or placebo gel, dosed to keep testosterone at 350–750 ng/dL and hematocrit at or below 54% (Cleveland Clinic; TCTMD).
After an average of 33 months, cardiovascular death, nonfatal heart attack or nonfatal stroke had occurred in 182 men (7.0%) on testosterone and 190 (7.3%) on placebo: a hazard ratio of 0.96 (95% CI 0.78–1.17). Testosterone was "noninferior": not worse than placebo. But atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%) and nonfatal arrhythmias needing treatment (5.2% vs 3.3%) were significantly more common with testosterone. Pulmonary embolism was also more frequent (0.9% vs 0.5%), though the paper did not report a significance test for it.
Event rates on testosterone gel vs placebo, men aged 45–80
Lincoff et al., NEJM 2023, as reported by Cleveland Clinic and TCTMD; mean follow-up 33 months. Major heart events = cardiovascular death, nonfatal heart attack or nonfatal stroke (HR 0.96). Fractures: Snyder et al., NEJM 2024, 5,204 men, median 3.19 years (HR 1.43, 95% CI 1.04–1.97).
What the headline leaves out
- Many men stopped. About 61% in both groups discontinued treatment, and 20.8% withdrew before the end. Average time on treatment was about 22 months.
- One product, one kind of man. A daily gel dosed to normal levels in men with confirmed low testosterone. It says little about injections, high doses or men with normal levels.
- "Not worse" isn't "better". It wasn't designed to show testosterone lowers heart risk.
What the FDA changed
On 28 February 2025 the FDA announced class-wide labeling changes: removing Boxed Warning language about an increased risk of adverse cardiovascular outcomes, adding TRAVERSE's results to all testosterone labels, and adding a new warning about increased blood pressure to products that didn't already carry one, because ambulatory blood pressure studies "confirmed an increase in blood pressure with use of all testosterone products, class-wide". It kept the "Limitation of Use" language for age-related hypogonadism (FDA).
What Testosterone Actually Does
Evidence: Moderate to strong — several randomised trialsThe best benefit data comes from TRAVERSE sub-studies and the NIH-funded Testosterone Trials (TTrials). The TTrials screened 51,085 men to find 790 aged 65 or older with testosterone below 275 ng/dL and symptoms; average age 72. They used testosterone or placebo gel for a year (ACC summary of Snyder, NEJM 2016; NIH).
What TRT does and doesn't do, by trial
| Outcome | Trial | Testosterone vs placebo | Verdict |
|---|---|---|---|
| Sexual activity and desire | TTrials, 790 men 65+ | Activity, desire and erectile function improved more than placebo | Helps |
| Sexual function, low libido | TRAVERSE, 1,161 men | Activity and desire improved; erectile function didn't | Helps, partly |
| Spine bone density | TTrials, 211 men | +7.5% vs +0.8% | Helps |
| Unexplained anemia | TTrials, 62 men with unexplained anemia | 58.3% vs 22.2% no longer anemic at 1 year | Helps |
| Anemia, any cause | TRAVERSE, 815 anemic men | 45% vs 33.9% corrected at 1 year | Helps |
| Walking ≥50 m further | TTrials, all men | 20.5% vs 12.6% not significant in the physical-function trial alone | Small |
| Vitality and fatigue | TTrials | No significant benefit | No |
| Mood and energy | TRAVERSE, 5,204 men | Modest but significant improvement | Small |
| Prediabetes to diabetes | TRAVERSE, 1,175 men | 7.8% vs 10.7% at 1 year not significant | No |
| Major depression | TRAVERSE | Symptoms didn't improve | No |
| Fractures | TRAVERSE, 5,204 men | 3.50% vs 2.46% HR 1.43 | Worse |
| Coronary plaque | TTrials, 138 men | Noncalcified plaque grew 41 mm³ more P = 0.003 | Worse on scans |
Snyder, NEJM 2016; Snyder, Roy, JAMA Intern Med 2017; Budoff, JAMA 2017; Pencina, JCEM 2024 and JAMA Netw Open 2023; Bhasin, JAMA Intern Med 2024 and JCEM 2024; Snyder, NEJM 2024. "Helps" means a statistically significant average benefit, not that every man will notice it.
Sex, mood and energy
Sexual function is the most consistent benefit. In TRAVERSE's study of 1,161 men with low libido, two years of treatment improved sexual activity, desire and hypogonadal symptoms, but not erectile function (Pencina, JCEM 2024).
Energy is where expectations outrun the evidence. The TTrials found no significant benefit for vitality, though men on testosterone reported slightly better mood. TRAVERSE, with far more men, found "modest but significantly greater improvements in mood and energy" on testosterone: real, but small. The AUA tells doctors to inform patients that evidence on energy, fatigue, cognition and quality of life is inconclusive. In TRAVERSE, 50.8% of men had at least mild depressive symptoms at the start (a PHQ-9 score above 4), but according to lead author Shalender Bhasin, testosterone didn't improve symptoms in men with major depressive disorder: TRT "does not represent an effective treatment option for most men with clinical depressive disorders" (Endocrine News; Bhasin, JCEM 2024).
Bone, blood and a surprise
Testosterone raised spine bone density and corrected anemia in more men than placebo did (MDedge, on the 2017 TTrials papers; Healio, on Pencina 2023). But denser bone didn't mean fewer breaks. In TRAVERSE's fracture sub-study, 91 men on testosterone (3.50%) had a clinical fracture against 64 on placebo (2.46%) (Snyder, NEJM 2024). The cause is unclear, but the authors concluded that testosterone did not lower fracture rates, so fracture prevention isn't a reason to take it.
Plaque and blood sugar
The TTrials cardiovascular study scanned the coronary arteries of 170 men; 138 completed it. Noncalcified plaque rose from a median of 204 to 232 mm³ on testosterone and from 317 to 325 mm³ on placebo, an estimated difference of 41 mm³ (AuntMinnie, on Budoff, JAMA 2017). That's a scan finding in a small group, not heart attacks, and TRAVERSE later found no rise in heart events. In 1,175 TRAVERSE men with prediabetes, progression to diabetes didn't differ significantly, and the authors concluded TRT alone "should not be used as a therapeutic intervention to prevent or treat diabetes in men with hypogonadism" (Bhasin, JAMA Intern Med 2024).
The Risks Nobody Advertises
Evidence: Strong — guidelines and FDA labelingFertility. Outside testosterone tells the pituitary to stop signalling the testes. One gel's FDA label says that with large doses, spermatogenesis "may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH)", which could lower sperm count (AndroGel 1% label). The AUA says it "should not be prescribed to men who are currently trying to conceive". If children are possible, raise it at the first appointment.
Thick blood. Testosterone raises red blood cell production, which is why it helps anemia and why hematocrit must be watched. The Endocrine Society's evidence review defines erythrocytosis as a hematocrit above 54%, and the FDA label says to stop therapy if hematocrit becomes elevated until it falls.
Prostate and blood pressure. In TRAVERSE's prostate study, high-grade prostate cancer was rare in both groups (0.19% vs 0.12%, not significantly different), though PSA rose more on testosterone (Bhasin, JAMA Netw Open 2023). And since the FDA now says all testosterone products raise blood pressure, it's worth asking how your blood pressure will be monitored.
The online clinic question. A good "low-T" service looks like the guidelines: two morning tests, LH and FSH, PSA and hematocrit before starting, a fertility conversation, then testosterone checks every 6 to 12 months. The AUA prefers commercially made products over compounded ones, aims for the middle of the normal range (about 450–600 ng/dL), and suggests discussing stopping after three to six months if symptoms haven't improved. A clinic that prescribes after one afternoon test isn't following the evidence.
Sleep and Weight Move the Number
Evidence: Moderate — meta-analysis and a small lab studyWeight. A 2013 meta-analysis of 24 studies in men with obesity found testosterone rose after both low-calorie diets and bariatric surgery, roughly three times more after surgery, and the amount of weight lost best predicted the rise (Corona, Eur J Endocrinol 2013). The authors note that randomised trials of diet and exercise are few and conflicting, so treat this as a strong association.
Sleep. In a University of Chicago study published in JAMA in 2011, ten healthy men averaging 24 slept under five hours a night for eight nights. Their testosterone fell 10% to 15%, lowest in the afternoon, and their mood and vigor sank. Testosterone falls about 1% to 2% a year with age (UChicago Medicine). Small and short, but a reason to test after normal nights and to ask about sleep apnea.
Questions to Ask Your Doctor
- Were both tests early-morning, and were both low? If not, repeat them.
- What are my LH, FSH and, if needed, prolactin and free testosterone?
- Which of my symptoms is this likely to help? Sex drive, probably. Energy and mood, much less certain.
- How will we monitor it, and when do we stop if it isn't working?
- Should I fix sleep and weight first?
Who shouldn't start casually: men with normal levels who want an edge; men planning children; and, per the Endocrine Society, men with prostate or breast cancer, a PSA above 4 ng/mL (or above 3 ng/mL in men at high risk) without further urological evaluation, high hematocrit, untreated severe sleep apnea, uncontrolled heart failure, a heart attack or stroke in the past six months, or a clotting disorder. Given the TRAVERSE signals, men with atrial fibrillation or past blood clots may want to discuss them with their doctor or cardiologist.
Frequently Asked Questions
A real treatment for a specific problem.
For men with properly confirmed low testosterone and symptoms, the biggest trial so far is reassuring on heart attacks and strokes. Testosterone reliably helps sex drive, bone density and anemia. It does little for fatigue, doesn't prevent diabetes or treat depression, and it came with more atrial fibrillation, kidney injury, lung clots and fractures.
That makes it a medical decision, not a lifestyle upgrade. Get two proper morning tests, sort out sleep and weight, and if you start, make sure someone checks your hematocrit, PSA and blood pressure. Talk it through with your doctor.
Sources
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine 2023;389(2):107–117 (doi:10.1056/NEJMoa2215025). Figures as reported by Cleveland Clinic (16 June 2023), TCTMD (16 June 2023) and the American College of Cardiology.
- US Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. 28 February 2025.
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. Journal of Urology 2018;200(2):423–432 (doi:10.1016/j.juro.2018.03.115); reviewed and validity confirmed 2024.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism 2018;103(5):1715–1744.
- Wu FCW, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. New England Journal of Medicine 2010;363(2):123–135 (doi:10.1056/NEJMoa0911101). Prevalence as reported by ACP Internist Weekly and symptoms by HealthDay.
- Baillargeon J, Urban RJ, Ottenbacher KJ, et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Internal Medicine 2013;173(15):1465–1466 (doi:10.1001/jamainternmed.2013.6895). As reported by the University of Texas Medical Branch: Testosterone therapy increased threefold in 10 years.
- Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. New England Journal of Medicine 2016;374(7):611–624 (doi:10.1056/NEJMoa1506119). As summarised by the American College of Cardiology and the National Institutes of Health (18 February 2016).
- Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA 2017;317(7):708–716 (doi:10.1001/jama.2016.21043). As reported by AuntMinnie and LA BioMed (21 February 2017).
- Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone. JAMA Internal Medicine 2017;177(4):471–479 (doi:10.1001/jamainternmed.2016.9539). Roy CN, Snyder PJ, Stephens-Shields AJ, et al. Association of testosterone levels with anemia in older men. JAMA Internal Medicine 2017;177(4):480–490 (doi:10.1001/jamainternmed.2016.9540). As reported by MDedge.
- Snyder PJ, Bauer DC, Ellenberg SS, et al. Testosterone treatment and fractures in men with hypogonadism. New England Journal of Medicine 2024;390(3):203–211 (doi:10.1056/NEJMoa2308836).
- Bhasin S, Lincoff AM, Nissen SE, et al. Effect of testosterone on progression from prediabetes to diabetes in men with hypogonadism: a substudy of the TRAVERSE randomized clinical trial. JAMA Internal Medicine 2024;184(4):353–362, published online 5 February 2024 (doi:10.1001/jamainternmed.2023.7862).
- Pencina KM, Travison TG, Cunningham GR, et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology & Metabolism 2024;109(2):569–580 (doi:10.1210/clinem/dgad484).
- Pencina KM, Travison TG, Artz AS, et al. Efficacy of testosterone replacement therapy in correcting anemia in men with hypogonadism. JAMA Network Open 2023;6(10):e2340030 (doi:10.1001/jamanetworkopen.2023.40030). As reported by Healio.
- Endocrine News. Eureka! The Top Endocrine Science of 2024 – Part IV (on Bhasin S, Seidman SN, Travison TG, et al. Depressive syndromes in men with hypogonadism in the TRAVERSE trial: response to testosterone-replacement therapy. JCEM 2024;109(7):1814–1826, doi:10.1210/clinem/dgae026).
- Bhasin S, Travison TG, Pencina KM, et al. Prostate safety events during testosterone replacement therapy in men with hypogonadism: a randomized clinical trial. JAMA Network Open 2023;6(12):e2348692 (doi:10.1001/jamanetworkopen.2023.48692).
- US Food and Drug Administration. AndroGel (testosterone gel) 1% prescribing information, revised October 2016.
- Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology 2013;168(6):829–843 (doi:10.1530/EJE-12-0955).
- Leproult R, Van Cauter E. Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA 2011;305(21):2173–2174 (doi:10.1001/jama.2011.710). As reported by UChicago Medicine.